Leukemias | Clinical

Clinical Trials Are Underway on Novel Approaches to CML-Resistant BCR-ABL1 Inhibitors

November 27, 2020

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

Doctors Debate: Is Intensive or Low-Intensity Chemotherapy Plus BCR-ABL TKI Therapy Best for Treatment of Ph+ ALL?

November 09, 2020

During a debate, Nicholas J. Short, MD, argued that intensive chemotherapy combined with a BCR-ABL tyrosine kinase inhibitor still holds the place of standard-of-care treatment for Phildelphia chromosome acute lymphoblastic leukemia, while Sabina Chiaretti, MD, PhD, made the case for targeted therapy.

Targeted Agents Induce Significant Efficacy in Older, Frail Patients With ALL

October 17, 2020

On the treatment of adult patients with acute lymphoblastic leukemia, long-term cure rates in elderly populations, or those older than 55 to 60 years of age, are approximately 15% to 20% and represent a clinically unmet need in this hematologic cancer.

Modified Pediatric Regimen Improves Outcomes in Young Adult Patients With Acute Lymphoblastic Leukemia

September 09, 2020

Using a modified pediatric regimen to treat adolescents and young adults with acute lymphoblastic leukemia led to superior outcomes compared with historical adult ALL regimen results, according to a retrospective analysis that evaluated 95 AYAs aged 14 to 39 years. Findings were presented at the eighth annual Society of Hematologic Oncology virtual meeting.

Considerations for Choosing Between Newer Agents in R/R B-Cell ALL

September 09, 2020

In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also raising clinical questions of how to choose among these agents and what is the best option for the patient at which time.

CC-486 Constitutes Standard of Care for Subset of Patients with AML

September 05, 2020

In an interview with Targeted Oncology Guillermo Garcia-Manero, MD, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission acute myeloid leukemia.

FDA Approves CC-486 as Maintenance Therapy in Acute Myeloid Leukemia

September 01, 2020

The FDA granted approval to the oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg), as a maintenance treatment for adult patients with acute myeloid leukemia who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.

Novel STAMP Inhibitor Asciminib Meets Primary End Point in Phase 3 Study of Chronic Myeloid Leukemia

August 26, 2020

The primary end point of statistically superiority in major molecular response rate at 24 weeks was met with asciminib versus bosutinib as treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the phase 3 ASCEMBL study.